What should I do if I become drug-resistant after taking Fostamatinib?

Fostamatinib (Fostamatinib) is a drug specifically designed to treat chronic immune thrombocytopenia (ITP). However, in clinical practice, some patients may develop drug resistance, thus affecting the therapeutic effect. When faced with drug resistance, formulating an appropriate treatment plan requires comprehensive consideration of individual differences and specific conditions of the patient.

When assessing drug resistance, careful monitoring of platelet counts and other relevant indicators is required while patients are taking fotantinib. If a patient's platelet level does not reach expectations or fluctuates significantly after a reasonable course of treatment, doctors should consider the possibility of drug resistance. At this point, a thorough evaluation is usually performed to rule out other potential factors, such as drug interactions, comorbidities, or failure to follow medical advice, to confirm the true nature of resistance.

In view of the phenomenon of drug resistance, the first step can be to consider adjusting the treatment plan. Physicians can moderately increase the dose of fotantinib if the initial dose is not effective. At the same time, the combined use of other therapeutic drugs, such as glucocorticoids or other immunomodulators, is also an effective strategy. This combination therapy not only helps overcome drug resistance but also improves overall platelet counts.

If patients continue to fail to respond to fotantinib, they may need to switch to other types of treatment options. For example, other novel drugs may be considered, or, in some severe cases, splenectomy surgery may be considered. The spleen plays an important role in the immune response, and its removal may help reduce damage to platelets, thereby improving platelet counts.

Reference materials:https://karger.com/aha/article/147/3/333/864227/Fostamatinib-or-Thrombopoietin-for-the-Treatment